The last few weeks, I’ve been exploring different ways of trying to communicate the value of building a data driven biotech startup, as opposed to one that uses data in more or less the way that biologists and chemists have been doing for decades. One of the reasons this is hard is that many biotechs that claimed they were going to use data or AI/ML to revolutionize drug development have either fizzled out or have yet to deliver the kinds of results that we were promised. I’m not saying we haven’t seen progress from them - just not as much as many were hoping for.
The bottom line is too far away
The bottom line is too far away
The bottom line is too far away
The last few weeks, I’ve been exploring different ways of trying to communicate the value of building a data driven biotech startup, as opposed to one that uses data in more or less the way that biologists and chemists have been doing for decades. One of the reasons this is hard is that many biotechs that claimed they were going to use data or AI/ML to revolutionize drug development have either fizzled out or have yet to deliver the kinds of results that we were promised. I’m not saying we haven’t seen progress from them - just not as much as many were hoping for.